STOCK TITAN

Crinetics Pharmaceuticals Inc - CRNX STOCK NEWS

Welcome to our dedicated news page for Crinetics Pharmaceuticals (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Crinetics Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Crinetics Pharmaceuticals's position in the market.

Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. granted non-qualified stock options to ten new non-executive employees under the 2021 Inducement Plan. The options have an exercise price of $45.90 per share and will vest over four years. This move aims to incentivize new employees and align their interests with the company's performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.16%
Tags
none
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) announces positive topline results from the PATHFNDR-2 Phase 3 study on paltusotine for acromegaly treatment. 56% of participants achieved IGF-1 ≤1.0 xULN vs. 5% on placebo, meeting primary and secondary endpoints. No serious adverse events reported, supporting planned NDA submission in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.11%
Tags
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) announced positive topline results from its Phase 2 study of paltusotine for carcinoid syndrome. The study showed rapid and sustained reductions in flushing episodes and bowel movements, with overall positive patient outcomes. The company plans to move towards Phase 3 trials by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) granted non-qualified stock options to five new non-executive employees under the 2021 Inducement Plan. The options have an exercise price of $42.29 per share and will vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
none
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) reported financial results, achieving milestones in 2023 with positive data from Phase 3 studies on paltusotine for acromegaly and carcinoid syndrome. Pending results from PATHFNDR-2 study, NDA submission for acromegaly is expected in 2H 2024. The company announced a $350 million private placement financing to support growth and expects transformational years in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) announced a private placement of 8,333,334 shares of its common stock at $42.00 per share, expecting to raise around $350 million. The private placement targets institutional and accredited healthcare specialist investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
none
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) will announce its Q4 and full-year 2023 financial results on February 28, 2024. The company will host a conference call and webcast to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
conferences earnings
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) granted non-qualified stock options to nine new non-executive employees. The options, with an exercise price of $39.46 per share, total 73,000 shares and will vest over four years. This grant is in line with the 2021 Inducement Plan to attract new talent to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.42%
Tags
none
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) granted non-qualified stock options to 8 new non-executive employees under the 2021 Employment Inducement Incentive Award Plan. The options have an exercise price of $37.60 per share and will vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences
Crinetics Pharmaceuticals Inc

Nasdaq:CRNX

CRNX Rankings

CRNX Stock Data

3.47B
64.74M
1.92%
97.19%
6.3%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Diego

About CRNX

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.